Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Secukinumab vs placebo in moderate to severe chronic plaque psoriasis (Phase 3, Hungary)
2016-000524-25Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in plaque psoriasis comparing Secukinumab with Placebo (2 arms). Primary endpoints: PASI 75 response at Week 12 and IGA mod 2011 score 0 or 1 at Week 12. Started Nov 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2016-000524-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000524-25.